Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

FibroGen, Inc (FGEN)

Pharmaceutical Preparations

https://www.fibrogen.com

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

409 ILLINOIS STREET
SAN FRANCISCO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

11/14/2014

Market Cap

37,549,974

Shares Outstanding

98,340,000

Weighted SO

98,340,219

Total Employees

N/A

Upcoming Earnings

08/05/2024

Similar Tickers

ARDX --.--%

ZURA --.--%

HEPA --.--%

AVRO --.--%

VSTM --.--%

MREO --.--%

BPMC --.--%

AGIO --.--%

DAWN --.--%

Beta

0.7140

Last Div

0.0000

Range

0.333-2.93

Chg

0.0040

Avg Vol

2629993

Mkt Cap

37549974

Exch

NASDAQ

Country

US

Phone

415 978 1200

DCF Diff

5.9751

DCF

15.7749

Div Yield

0.0000

P/S

0.2160

EV Multiple

-0.4352

P/FV

-0.1607

Div Yield %

0.0000

P/E

-0.2218

PEG

-0.0304

Payout

-0.0134

Current Ratio

1.4097

Quick Ratio

1.2387

Cash Ratio

0.9470

DSO

73.3129

DIO

228.4297

Op Cycle

301.7426

DPO

89.3859

CCC

212.3567

Gross Margin

0.7665

Op Margin

-0.9186

Pretax Margin

-0.9864

Net Margin

-0.9684

Eff Tax Rate

0.0004

ROA

-0.5741

ROE

0.8193

ROCE

-1.1040

NI/EBT

0.9818

EBT/EBIT

1.0738

EBIT/Rev

-0.9186

Debt Ratio

0.3595

D/E

-0.4537

LT Debt/Cap

-0.6309

Total Debt/Cap

-0.8304

Int Coverage

-15.4964

CF/Debt

-1.9166

Equity Multi

-1.2620

Rec Turnover

4.9787

Pay Turnover

4.0834

Inv Turnover

1.5979

FA Turnover

2.4098

Asset Turnover

0.5928

OCF/Share

-2.0235

FCF/Share

-2.0333

Cash/Share

1.4095

OCF/Sales

-1.1622

FCF/OCF

1.0048

CF Coverage

-1.9166

ST Coverage

-13.0073

CapEx Coverage

-206.5603

Div&CapEx Cov

-62.4856

P/BV

-0.1607

P/B

-0.1607

P/S

0.2160

P/E

-0.2218

P/FCF

-0.1850

P/OCF

-0.1848

P/CF

-0.1848

PEG

-0.0304

P/S

0.2160

EV Multiple

-0.4352

P/FV

-0.1607

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Aug 23, 22:04 Catalyst Accelerator Ogden Selects 11 Companies for Fall 2024 Cohort in Partnership with the Department of the Air Force Digital Transformation Office GlobeNewswire Inc. Dec 09, 17:02 FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting GlobeNewswire Inc. Dec 09, 17:02 FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting GlobeNewswire Inc. Dec 09, 17:02 FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting GlobeNewswire Inc. Dec 09, 17:02 FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting GlobeNewswire Inc. Dec 09, 17:02 FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting GlobeNewswire Inc. Dec 09, 17:02 FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting GlobeNewswire Inc. Dec 09, 17:02 FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting GlobeNewswire Inc. Dec 09, 17:02 FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting GlobeNewswire Inc. Dec 09, 17:02 FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting GlobeNewswire Inc. Dec 09, 17:02 FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting GlobeNewswire Inc. Dec 09, 17:02 FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting GlobeNewswire Inc. Dec 09, 17:02 FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

Revenue Product Segmentation